TL;DR:
- Acer Medical, an Acer Group company, has introduced aiMed, a next-generation generative AI medical documentation system.
- The system uses real-time AI processing to convert voice or text notes into structured electronic medical records (EMRs), reducing the administrative burden on healthcare professionals.
- aiMed is designed to enhance efficiency, minimize documentation errors, and improve patient care by freeing up clinicians’ time.
- Acer Medical also highlighted its VeriSee platform, an AI-assisted ophthalmology analysis tool that is already deployed in over 500 clinics across 14 international markets, including Malaysia.
- The company aims to accelerate the global adoption of smart, sustainable medical solutions through a combination of generative AI for documentation and AI-powered screening tools.
Tackling Healthcare’s Most Pressing Challenge
At its global press conference ahead of IFA 2025, Acer Medical unveiled aiMed, its innovative generative AI medical documentation system. This new solution directly addresses a major challenge in modern healthcare: the administrative burden of clinical documentation, which can consume up to 25% of a healthcare provider’s working hours.
aiMed leverages advanced, real-time AI processing to convert voice dictation or typed notes into accurate and compliant electronic medical records (EMRs). By automating this task, the system aims to:
- Reduce administrative workload, allowing more time for direct patient care.
- Minimize documentation errors in medical records.
- Enhance patient safety and overall quality of care.
- Ensure interoperability with existing hospital information systems.
“Our goal with aiMed is to give doctors and healthcare providers their time back,” said a spokesperson for Acer Medical. “By streamlining a traditionally time-consuming process, we’re not just improving efficiency; we’re empowering them to focus on what matters most—their patients.”
The Power of AI in Diagnosis and Documentation
In addition to aiMed, Acer Medical highlighted its successful VeriSee platform. This AI-assisted ophthalmology analysis platform can analyze retinal images in seconds to screen for a range of conditions, including:
- VeriSee DR: Diabetic Retinopathy
- VeriSee AMD: Age-related Macular Degeneration
- VeriSee GLC: Glaucoma Suspect
The VeriSee platform has already proven its value, with deployments in over 500 clinics and hospitals across 14 international markets. Notably, Acer Medical has a presence in Malaysia, with its VeriSee AMD software having received regulatory approval from the Medical Device Authority (MDA) of Malaysia in 2024.
Acer Medical is committed to a future where AI and digital solutions enhance healthcare efficiency and improve patient outcomes globally.